This entrepreneur’s mission is to tackle global health challenges
If the past year and a half has shown anything, it’s that pharmaceutical and biotech startups are paving the way for a new future in human health. The industry remains hot as the world celebrates the success of Moderna and BioNTech mRNA-based vaccines.
One of these breakthrough companies is based in Toronto Mountain Valley MD (MVMD). They are developing proprietary technology that could be the key to making existing world-class drugs and vaccines more effective, more affordable, and available around the world. They are also working on a drug to end many hard-to-treat cancers.
At the helm is experienced entrepreneur Dennis Hancock. He has over 25 years of experience representing globally recognized brands in the automotive, pharmaceuticals, technology, telecommunications and financial services industries. Now he is leading the way to bring MVMD to the top of the biotech industry.
A man on a mission
Dennis Hancock initially joined MVMD as a consultant in 2018 after hearing the company was exploring new uses for the antiparasitic drug Ivermectin, a drug widely used since the late 1970s to cure some of the world’s most persistent parasitic threats.
Researchers have long known that the drug has unique properties that could make it useful in fighting other diseases. The most important of these is cancer.
Dennis had seen many of the people closest to her losing their lives to illness and jumped at the opportunity to help pursue potential treatment for her. When the opportunity presented itself, Dennis was more than happy to take on the role of CEO to help grow the company and brand on the global stage.
In doing so, he immediately put his mark on the company, insisting that they do everything in their power to turn their research into practical products. In this regard, he noted, “I wanted us to adopt solutions that evolve at the speed of technology and I fostered a corporate culture of rapid failure. In my opinion, if the company doesn’t make mistakes every day, it doesn’t. try hard enough. “
Encouraging first results
Dennis’ mindset has helped MVMD continue early testing of its proprietary version of ivermectin, called Ivectosol, as an enhancer for existing cancer drugs. His belief in drugs paid off early on.
In early model tests for triple negative breast cancer, oral ivermectin combined with a checkpoint inhibitor increased the complete response rate to over 40%, while the checkpoint inhibitor acting alone was only 5%. Dennis says the result has encouraged the company to take it further. “It’s a great result, and MVMD is moving forward at full speed. It’s an intimidating mountain to climb, but one that could lead to the ultimate reward: a world where our bodies can fight cancer and win.”
Pursue a technology licensing model
In an attempt to accelerate MVMD’s breakthroughs in the marketplace and into the hands of those in need, Dennis has guided the company in establishing partnership relationships with a select circle of collaborators in the pharmaceutical industry. “To keep our company focused on its research and technological development, I thought it would be best to partner with established companies that have the scale and production facilities to turn our technology into marketable products. as quickly as possible. ”
“The ability to expand our impact comes through working with large-scale partners who see what we see and believe in the change we pursue. For us, staying agile, strong and entrepreneurial is the only way to make our mission a reality, ”he continued.
It’s an approach that Dennis says dovetails with another project the company is working on: proprietary technology that, together with existing vaccines and drugs, eliminates the need for costly and complex storage and transport in The cold chain.
This is the same problem complicating the campaign to immunize the world against the ongoing COVID-19 pandemic. Dennis sees it as a challenge. In a recent interview, it is explained: “More than 35 billion dollars of vaccines are wasted each year. MVMD’s technology eliminates the need for the traditional cold chain, which means the people who need vaccines most, in underserved countries with hot climates, will get them. . “
Since Dennis has positioned MVMD as a technology licensor rather than a direct pharmaceutical producer, once the technology is ready, they are set to have a global impact.
Gather for the good of all
According to Dennis, it’s the vision that energizes the entire company. “MVMD is founded on the pursuit of a positive impact on the health and well-being of the world. It is led by a specialized collective of scientists, doctors and entrepreneurs united in their vision of a world where everyone can live their best life. “
When discussing the spirit of his team, Dennis says “They trust the limitless power of science, fueled by human empathy, all with the goal of freeing millions of people from the tragedy of preventable disease. ”
Together, Dennis and his team believe they will change the face of modern medicine.